Houston Society of Clinical Pathologists and The Methodist Hospital Department of Pathology and Genomic Medicine combine to present

Houston lung symposium

April 28-29, 2012

Program Director: Philip T. Cagle, M.D.
The Methodist Hospital Research Institute, Texas Medical Center, Houston
Program Director
Philip T. Cagle, M.D.
The Methodist Hospital Research Institute
Medical Director, Pulmonary Pathology
Department of Pathology and Genomic Medicine
Professor of Pathology and Laboratory Medicine
Weill Medical College of Cornell University

Needs Assessment:
There have many advances and paradigm shifts in pulmonary pathology and medicine, especially lung cancer, over the past few years. These include:

(1) New targeted therapies for lung cancer and associated biomarkers, including new lung cancer biomarker guidelines under development by the College of American Pathologists, the International Association for the Study of Lung Cancer and the Association for Molecular Pathology.

(2) New pathologic classification for adenocarcinoma of the lung proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society.

(3) New staging protocol for lung cancer by the American Joint Committee on Cancer, the International Union for Cancer Control and the College of American Pathologists.


(5) New guidelines for the pathologic and clinical diagnosis and management of idiopathic pulmonary fibrosis by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, the Latin American Thoracic Society, the Society of Thoracic Radiology and the Pulmonary Pathology Society.

(6) Development of new pathology imaging techniques for the in-vivo microscopic-level diagnosis of pulmonary diseases.

Target Audience: This activity is directed towards practicing pathologists, pulmonologists and oncologists and trainees in the field of pathology, pulmonology and oncology.

Educational Methods: The program format will consist of didactic lectures with Q&A and discussions. Handouts will be provided.

Evaluation: Evaluation by questionnaire will address program content, presentation, and possible bias.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Texas Medical Association (TMA) and the Houston Society of Clinical Pathologists. The TMA is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The TMA designates this educational activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Disclosure: In order to meet the requirements of the ACCME it is the policy of The TMA that all individuals who are in a position to control the content of a CME activity (activity director, planning committee members, and faculty) disclose relevant financial relationships with commercial interests. All identified conflicts of interest are managed to help ensure that the educational material is scientifically based, accurate, and objectively presented. Faculty are also required to disclose any discussion of off-label or investigational uses of any commercial products or devices not yet approved in the United States. Specific disclosure will be made to the participants prior to the educational activity.
Faculty

Yung-Jue Bang, M.D.
Seoul National University Hospital
Seoul, Korea

Alain C. Borczuk, M.D.
Columbia University Medical Center
New York, New York

Paul Bunn, M.D.
University of Colorado Comprehensive Cancer Center
Denver, Colorado

Lucian Chirieac, M.D.
Brigham & Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Andrew Churg, M.D.
University of British Columbia
Vancouver, Canada

Thomas Colby, M.D.
Mayo Clinic Arizona
Scottsdale, Arizona

Sanja Dacic, M.D., Ph.D.
University of Pittsburgh
Pittsburgh, Pennsylvania

Lida P. Hariri, M.D., Ph.D.
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Juergen Hetzel, M.D.
University of Tuebingen
Tuebingen, Germany

James R. Jett, M.D.
Journal of Thoracic Oncology
National Jewish Health
Denver, Colorado

Keith Kerr, M.D.
Aberdeen Royal Infirmary
Aberdeen University Medical School
Scotland, United Kingdom

Marc Ladanyi, M.D.
Memorial Sloan-Kettering Cancer Center
New York, New York

Kevin O. Leslie, M.D.
Mayo Clinic Arizona
Scottsdale, Arizona

Neal I. Lindeman, M.D.
Brigham & Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Laura MacConaill, Ph.D.
Center for Cancer Genome Discovery
Dana-Farber Cancer Institute
Harvard Medical School
Boston Massachusetts

Jeffrey Myers, M.D.
University of Michigan
Ann Arbor, Michigan

Geoffrey R. Oxnard, M.D.
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Ignacio Wistuba, M.D.
The University of Texas MD Anderson Cancer Center

Stephen T. C. Wong, Ph.D., P.E.
The Methodist Hospital
Houston, Texas

Maureen F. Zakowski, M.D.
Memorial Sloan Kettering Cancer Center
New York, New York
Program Schedule

Educational Objectives:
Saturday, April 28, 2012
1. Understand and diagnose interstitial lung diseases in the context of updated concepts and classifications of these diseases
2. Differentiate benign from malignant neoplasms of the lung and pleura
3. Comprehend recently implemented and proposed changes to the pathology of lung cancer

7:45-8:00 am Welcome - Philip Cagle, M.D.

8:00-8:45 am Proposed New Classification of Lung Cancer
Keith Kerr, M.D.

8:45-9:30 am Dilemmas in Lung Cancer Staging
Sanja Dacic, M.D., Ph.D.

9:30-10:15 am Benign Tumors and Tumor-Like Conditions of the Lung
Alain Borczuk, M.D.

10:15-10:45 am Break

10:45-11:30 am Update on Mesothelioma
Lucian Chirieac, M.D.

11:30-12:00 pm Clinical Genotyping of Lung Cancer: Beyond EGFR and EML4-ALK, Beyond Adenocarcinoma
Marc Ladanyi, M.D.

12:00-12:30 pm Role of Cytopathology in the Molecular Diagnostics and Targeted Therapy of Lung Cancer
Maureen Zakowski, M.D.

12:30-1:00 pm Lunch

1:30-2:15 pm Separation of Benign versus Malignant Mesothelial Proliferations
Andrew Churg, M.D.

2:15-3:00 pm Update on Idiopathic Interstitial Pnuemonias
Thomas Colby, M.D.

3:00-3:30 pm Break

3:30-4:15 pm Pulmonary Pathology of the Rheumatic Diseases
Kevin Leslie, M.D.

4:15-5:00 pm The Changing Role of Pathology in Managing Patients with Unexplained Diffuse Lung Disease
Jeffrey Myers, M.D.

5:00-5:30 pm Panel Discussion

5:30 pm Adjournment - Philip T. Cagle, M.D.
Program Schedule

Educational Objectives:
Sunday, April 29, 2012
1. Be familiar with the role of current and future molecular targeted therapies, whole genome analysis and predictive biomarkers in the personalized health care of lung cancer patients
2. Appreciate advances in technology that impact the future early diagnosis and screening of lung cancer patients

7:45-8:00 am Welcome-Philip Cagle, M.D.
8:00-8:30 am Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Paul Bunn, M.D.
8:30-9:00 am EGFR, ALK and KRAS Molecular Testing in Lung Adenocarcinoma: Why, When and How
Neal I. Lindeman, M.D.
9:00-9:30 am Treatment of ALK-Positive NSCLC
Yung-Jue Bang, M.D.
9:30-10:00 am Strategies to Overcome Resistance to EGFR Target Therapies
Geoffrey R. Oxnard, M.D.
10:00-10:30 am Break
10:30-11:00 am Cryobiopsy in Pulmonary Diseases
Jurgen Hetzel, M.D.
11:00-11:30 am Advancing Personalized Cancer Medicine in Lung Cancer
Laura MacConaill, M.D.
11:30-12:30 pm Lunch
12:30-1:00 pm Volumetric Optical Frequency Domain Imaging of Lung Pathology: Improving Biopsy Sampling and Evaluation
Lida P. Hariri, M.D., Ph.D.
1:00-1:30 pm Lung Cancer Differential Diagnosis by Label-Free, Molecular Vibrational Imaging
Stephen T. C. Wong, Ph.D., P.E.
1:30-2:00 pm Screening for Lung Cancer: Who Should be Screened?
James Jett, M.D.
2:00-2:30 pm Molecular Pathology of Lung Cancer: Changes in Prevention and Therapy Paradigms
Ignacio Wistuba, M.D.
2:30-3:00 pm Panel Discussion
3:00 pm Adjournment-Philip T. Cagle, M.D.
**Harlan J. Spjut Award Dinner**

The Board of Directors of the Houston Society of Clinical Pathologists established the Harlan J. Spjut Award in 1989, upon the announcement of Dr. Spjut’s retirement, to recognize an individual who has demonstrated sustained and distinguished scholarly achievement in pathology or related disciplines.

This year’s recipient is **Thomas Wheeler, MD**, Professor and Chair of the Department of Pathology and Immunology at the Baylor College of Medicine.

Spouses, guest of conference recipients and other persons not registered for the Symposium are welcome to attend. However, due to limited space, advanced reservations are required. Please call (713) 524-4267 ext. 223 for more information.

**POLICY OF DISCLOSURE**

It is the policy of the Texas Medical Association that all planners and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity. Detailed disclosure will be made in the syllabus of the course materials.

**ACCOMMODATIONS**

A block of rooms has been set up at the Houston Marriott Hotel at the Texas Medical Center under the name of The Methodist Hospital at a discounted rate of $179 for Singles and doubles. Code: MEP, Rate Program: MEPA.

For reservations call: 1-800-465-4213.

**HOUSTON**

Houston is the fourth-largest city in the U.S. and more than 90 languages are spoken throughout the Houston area. Houston’s George Bush Intercontinental Airport (a Continental Airlines hub) is located 23 miles north of the Texas Medical Center and Hobby Airport (a Southwest Airlines hub) is located 12 miles southeast of the Texas Medical Center. The Texas Medical Center is the world’s largest medical complex, situated on 675 acres and housing 42 institutions and 13 patient care facilities.

**PARKING**

Parking is $12 for 7 hours or more.

Walking distance to MITIE:
- Garage 7 (off of John Freeman Blvd.)
- Garage 1 (off of Bertner Ave.)
- Garage 3 (corner of E. Cullen St. And Ross Sterling Ave.)
- Commons Garage (John P. McGovern Commons-Water Wall)

Near Houston Marriott Hotel:
- Smith Garage (Smith Tower)
- Scurlock Garage (Scurlock Tower)
Registration

Houston Society of Clinical Pathologists 53rd Annual Symposium &
The Methodist Hospital Lung Seminar
Saturday, April 28-29, 2012

Name: _____________________________________ Degree: ______
Address: __________________________________________________
City: ___________________________ State: ________ Zip: ___________
Ph: (____) _____-_________ Fax: (____) _____-_________
Institution/Affiliation: _________________________________________
Email: _________________________________@___________________
Specialty: ___________________________________________________
Designation: □ Student □ Res/Fellow □ Faculty □ Alumni □ Other

Prior to 3/30/12 After 3/30/12
Reg Type: 1 Day 2 Day Reg Type: 1 Day 2 Day
HSCP Member □ $275 □ $450 HSCP Member □ $300 □ $475
Res/Fellow □ $90 □ $150 Res/Fellow □ $115 □ $175
Non-Physician □ $115 □ $175 Non-Physician □ $175 □ $200

Your registration must be prepaid. NO REFUNDS AFTER March 20, 2012
Online registration: www.HoustonPathologists.org OR fax attention to
Stefanie Cunanan at (713) 528-0951

Payment Type: □ Check (payable to HSCP) □ Amex □ DC □ MC □ VISA
Name on Card: __________________________________________________
Account #: ___________________ - ___________________ - _______________ - ___________
Exp. Date: __________/_________
Spjut: __________________ (# of tickets) X $100= Total: __________________
($100/person)
Auth. Total Amt: $__________

Special Assistance: In compliance with the Americans with Disabilities Act, the
Houston Society of Clinical Pathologists will make reasonable efforts to accom-
date persons with disabilities at this meeting. Please call (713) 524-4267 ext. 223
53rd Annual Spring Symposium
And the
The Methodist Hospital Lung Seminar
Saturday, April 28-29, 2012

For more information log on to
www.HoustonPathologists.org
OR call (713) 524-4267 ext. 223